Verici Dx (OTCPK:VRCDF) Ending Cash Position

: $15.72 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

Verici Dx's Ending Cash Position for the quarter that ended in Jun. 2022 was $15.72 Mil.

Verici Dx's quarterly Ending Cash Position declined from Jun. 2021 ($14.55 Mil) to Dec. 2021 ($10.34 Mil) but then increased from Dec. 2021 ($10.34 Mil) to Jun. 2022 ($15.72 Mil).

Verici Dx's annual Ending Cash Position stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($10.34 Mil).

Verici Dx Ending Cash Position Historical Data

The historical data trend for Verici Dx's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data

Trend

Dec20

Dec21

Ending Cash Position

10.34

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22
Ending Cash Position	14.55	10.34	15.72

Verici Dx Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Verici Dx's Ending Cash Position for the fiscal year that ended in Dec. 2021 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	17.751	+	-7.411
	=	10.34

Verici Dx's Ending Cash Position for the quarter that ended in Jun. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	10.34	+	5.377
	=	15.72

Verici Dx Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Verici Dx's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (OTCPK:VRCDF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialisation: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels.

Verici Dx (OTCPK:VRCDF) Headlines

No Headlines